Study of Blood Sugar Control Using Continuous Glucose Monitor Compared to Hemoglobin A1c in Patients with Left Ventricular Assist Devices and Type 2 Diabetes

What this Trial Is About

Researchers are evaluating the accuracy of hemoglobin A1c, a common blood sugar control measurement over three months, in patients with implanted Left Ventricular Assist Devices LVADs. The study aims to compare A1c results with continuous glucose monitoring CGM data to see if A1c is a reliable indicator for this group. Additionally, the trial will explore whether CGM use can improve blood sugar control and reduce low blood sugar episodes in patients with type 2 diabetes and LVAD support. Participants diagnosed with type 2 diabetes and supported by a contemporary centrifugal flow LVAD will receive a Freestyle Libre 3 CGM device. They will use this device to monitor blood glucose continuously over about three months. Data from the CGM will be uploaded weekly via the LibreLink smartphone app for review by diabetes-trained providers. Based on these results, diet and medication adjustments may be made to manage blood sugar levels and prevent hypoglycemia or severe hyperglycemia. During the study, participants will have their average glucose levels measured by CGM, hemoglobin A1c, and fructosamine lab tests at three months. Researchers will track changes in antihyperglycemic medications and episodes of hypoglycemic unawareness. Participants must be able to use a smartphone app and attend a follow-up evaluation at three months. The study will monitor glucose control and treatment effects during this period, providing close consultation and support throughout.

A Study of Glycemic Control in Left Ventricular Assist